An estimated 6 to 8 million Americans are living with metabolic dysfunction-associated steatohepatitis, or MASH, the most aggressive form of fatty liver disease. For most of them, treatment options have been limited to weight loss, lifestyle changes, and a single FDA-approved medication. Now, results from a year-long clinical trial led by UC San Diego hepatologist Rohit Loomba suggest a fundamentally different approach could work: silencing the enzyme that drives fat production in the liver before damage takes hold.
The drug, called ION224 and developed by Ionis Pharmaceuticals, reduced liver fat and reversed tissue damage in patients with biopsy-confirmed MASH over 51 weeks of treatment. Published in The Lancet and announced by UC San Diego Health, the findings mark the first time a drug targeting the DGAT2 enzyme has demonstrated histological reversal of MASH in a rigorous, placebo-controlled trial.
How ION224 attacks liver fat at its source
ION224 belongs to a class of drugs called antisense oligonucleotides. These are short, synthetic molecules engineered to latch onto a specific strand of messenger RNA and prevent it from being translated into protein. In this case, the target is DGAT2, an enzyme that catalyzes one of the final steps in triglyceride assembly inside liver cells.
By intercepting DGAT2’s genetic instructions before the enzyme is ever produced, ION224 aims to shut down excess fat accumulation at its origin rather than managing the inflammation and scarring that follow. That distinction matters. Most existing approaches to MASH, including the thyroid hormone receptor agonist resmetirom (sold as Rezdiffra and approved by the FDA in March 2024), work through different metabolic pathways. ION224 is the first to validate DGAT2 inhibition specifically as a viable route to reversing MASH-related liver injury.
What the trial showed
The Phase 2 trial, designated ION224-CS2 and registered under NCT04932512, enrolled adults with biopsy-confirmed MASH across multiple clinical sites. Participants received subcutaneous injections of ION224 or a matching placebo once every four weeks for up to 49 weeks, with final assessments at week 51. The study was randomized, double-blind, and placebo-controlled, the gold standard design for evaluating drug efficacy.
Pathologists who examined liver biopsies taken before and after treatment found measurable improvements in participants who received ION224. According to the peer-reviewed Lancet paper, the drug reduced steatosis (the medical term for fat accumulation in liver tissue) and necroinflammatory activity, the combination of cell death and active inflammation that defines progressive MASH. These changes were graded using standardized histological scoring systems, lending rigor to the findings.
For patients with MASH, histological reversal is a significant threshold. Left unchecked, the disease can progress to cirrhosis, liver failure, and hepatocellular carcinoma. Slowing that progression is valuable; actually reversing the underlying tissue damage shifts the conversation entirely.
What the trial did not answer
Promising as the results are, several critical questions remain open as of June 2026.
Responder rates. The Lancet paper reports group-level histological improvements, but publicly accessible summaries do not break out what proportion of individual patients experienced meaningful reversal versus modest or no change. That granularity will matter when clinicians try to set expectations with patients.
Safety details. The trial’s registry confirms that safety was a formal study objective, and the 51-week duration provides a reasonable window for detecting adverse events. However, detailed safety data, including liver enzyme elevations, injection-site reactions, and serious adverse events, are available only in the full peer-reviewed text, not in institutional summaries. Patients and prescribers will need those numbers before weighing the drug’s risk-benefit profile.
Durability. The trial measured outcomes at the end of roughly one year of dosing. No published data yet describe what happens after patients stop receiving ION224. If DGAT2 activity rebounds quickly once injections cease, the benefit could prove temporary, requiring indefinite treatment. If the reversal holds, the clinical implications change dramatically. Follow-up studies will need to settle this.
Who benefits most. One intriguing but untested hypothesis is whether ION224 response correlates more strongly with baseline hepatic DGAT2 expression than with overall body mass index. If so, biopsy-based biomarker panels could eventually help clinicians identify the patients most likely to respond. For now, the available data do not report any validated predictive markers beyond standard clinical inclusion criteria.
Metabolic trade-offs. Blocking triglyceride synthesis in the liver raises a biological question: where do the lipid precursors go instead? Redirecting fatty acid flux could theoretically affect other organs or metabolic pathways. The Phase 2 data have not flagged obvious problems, but larger and longer studies will need to watch for downstream effects.
Where ION224 fits in a crowded pipeline
ION224 is entering a MASH treatment landscape that has shifted rapidly. Resmetirom became the first FDA-approved therapy for the disease in 2024, and several other candidates are in late-stage trials, including GLP-1 receptor agonists like semaglutide, which have shown liver-related benefits in addition to their metabolic effects. Survodutide, a dual glucagon and GLP-1 agonist, has also posted strong Phase 2 MASH data.
What sets ION224 apart is its mechanism. Rather than improving insulin sensitivity, activating thyroid hormone receptors, or promoting weight loss, it directly silences the gene responsible for a key fat-production enzyme. That precision could make it a candidate for combination therapy alongside drugs that work through complementary pathways, though no combination studies have been published yet.
The Phase 2 scale of the current trial also imposes inherent limits. Mid-stage studies are designed to detect signals of efficacy and safety, not to provide definitive proof that a drug will prevent progression to cirrhosis, reduce the need for liver transplantation, or improve survival. Larger Phase 3 trials with more diverse patient populations and longer follow-up will be required before regulators can determine whether ION224 merits broad approval.
What this means for patients right now
ION224 is not yet available outside of clinical trials, and no timeline for regulatory submission has been publicly announced as of June 2026. For the millions of people living with MASH, the practical reality has not changed overnight. Lifestyle modification, metabolic management, and, for eligible patients, resmetirom remain the current standard of care.
But the UC San Diego trial has accomplished something that shifts the scientific ground: it has shown, in a controlled setting, that targeting a single enzyme upstream of fat accumulation can reverse the tissue damage that defines MASH. If subsequent trials confirm that ION224 can sustain that reversal safely and slow or halt progression to cirrhosis, it could reshape how clinicians treat a disease that, until very recently, had no approved pharmacological options at all.
For now, the strongest takeaway is that DGAT2 inhibition works as a concept. The next phase of research will determine whether it works as a medicine.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
